Baudax Bio to Present at NobleCon18 Investor Conference
Baudax Bio (NASDAQ:BXRX) announced that CEO Gerri Henwood will present at the Noble Capital Markets’ 18th Annual Investor Conference on April 20, 2022, at 3:30 p.m. ET in Hollywood, Florida.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Baudax Bio (NASDAQ:BXRX) announced that CEO Gerri Henwood will present at the Noble Capital Markets’ 18th Annual Investor Conference on April 20, 2022, at 3:30 p.m. ET in Hollywood, Florida. A webcast of this presentation will be available the next day on the company's website along with an archived version for 90 days.
Additionally, Henwood will participate in breakout sessions on April 20 at 12:15 p.m. ET and April 21 at 10:45 a.m. ET, providing further engagement opportunities.
Details
News Market Reaction – BXRX
The recorded move for BXRX in the trading session of this news was +6.86%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., April 13, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will present at the Noble Capital Markets’ 18th Annual Investor Conference (NobleCon18), taking place in Hollywood, Florida on Wednesday, April 20, 2022, at 3:30 p.m. Eastern Time.
A webcast of the presentation will be available the following day on the “Events” page within the investors section of the Baudax Bio website at https://www.baudaxbio.com/news-and-investors. The webcast will be archived on the company’s website, the NobleCon website, and on Channelchek.com for 90 days following the event.
There is also the opportunity to meet with Ms. Henwood at two breakout sessions scheduled for Wednesday, April 20, 2022, at 12:15 p.m. ET and Thursday, April 21, 2022, at 10:45 a.m. ET.
About Baudax Bio
Baudax Bio is a pharmaceutical company focused on commercializing and developing innovative products for acute care settings. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBs) and a proprietary chemical reversal agent specific to these NMBs. For more information, please visit www.baudaxbio.com.
CONTACT:
Investor Relations Contact:
Argot Partners
Sam Martin / Kaela Ilami
(212) 600-1902
baudaxbio@argotpartners.com
Media Contact:
Argot Partners
David Rosen
(212) 600-1902
david.rosen@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.